Edition:
United States

Auris Medical Holding AG (EARS.OQ)

EARS.OQ on NASDAQ Stock Exchange Capital Market

0.45USD
2:48pm EST
Change (% chg)

$-0.01 (-3.18%)
Prev Close
$0.46
Open
$0.46
Day's High
$0.47
Day's Low
$0.41
Volume
402,777
Avg. Vol
841,658
52-wk High
$6.59
52-wk Low
$0.23

Latest Key Developments (Source: Significant Developments)

Auris Medical Holding AG Entered Into Sales Agreement With A.G.P./Alliance Global Partners
Friday, 30 Nov 2018 03:06pm EST 

Nov 30 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL HOLDING AG - ENTERED INTO A SALES AGREEMENT WITH A.G.P./ALLIANCE GLOBAL PARTNERS.AURIS MEDICAL HOLDING AG - MAY OFFER AND SELL COMMON SHARES OF THE COMPANY, NOMINAL VALUE CHF 0.02 PER SHARE, FROM TIME TO TIME THROUGH A.G.P..  Full Article

Thomas Meyer Says Raises Stake In Auris Medical Holding To 27.1 Pct As Of Nov. 19-SEC Filing
Wednesday, 21 Nov 2018 04:41pm EST 

Nov 21 (Reuters) - Auris Medical Holding AG ::THOMAS MEYER SAYS RAISES STAKE IN AURIS MEDICAL HOLDING AG TO 27.1 PERCENT AS OF NOVEMBER 19 FROM A 24.4 PERCENT STAKE AS OF JULY 17 - SEC FILING.  Full Article

Auris Medical Announces Results Of Pre-IND Meeting With FDA For AM-201 Program In Olanzapine-Induced Weight Gain
Tuesday, 20 Nov 2018 09:20am EST 

Nov 20 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL ANNOUNCES RESULTS OF PRE-IND MEETING WITH FDA FOR AM-201 PROGRAM IN OLANZAPINE-INDUCED WEIGHT GAIN.AURIS MEDICAL HOLDING AG - COMPANY PLANS TO INITIATE A PHASE 1 PHARMACOKINETIC/PHARMACODYNAMIC STUDY IN Q1 OF 2019 TO EVALUATE AM-201.AURIS MEDICAL- FDA SUPPORTS PLANNED CONDUCT OF MULTIPLE DOSE PHASE 1 TRIAL WITH AM-201 ADMINISTERED TO HEALTHY SUBJECTS IN COMBINATION WITH OLANZAPINE.AURIS MEDICAL HOLDING AG - FOLLOWING READ-OUT FROM STUDY, CO EXPECTS TO FILE IND APPLICATION FOR AM-201 LATER IN 2019.AURIS MEDICAL-FDA ENDORSED WEIGHT GAIN NORMALIZED TO BASELINE BODY WEIGHT VERSUS PLACEBO AS REASONABLE PRIMARY EFFICACY ENDPOINT FOR SUBSEQUENT PHASE 2 TRIAL.  Full Article

Auris Medical Receives FDA Guidance At Type C Meeting For AM-111
Thursday, 30 Aug 2018 08:15am EDT 

Aug 30 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL RECEIVES FDA GUIDANCE AT TYPE C MEETING FOR AM-111 IN THE TREATMENT OF SUDDEN SENSORINEURAL HEARING LOSS.AURIS MEDICAL HOLDING AG - TYPE C MEETING HAD BEEN REQUESTED BY COMPANY FOLLOWING RESULTS OF HEALOS PHASE 3 TRIAL.AURIS MEDICAL - FDA REVIEWED PROPOSED CONCEPT FOR PIVOTAL TRIAL WITH AM-111 0.4 MG/ML IN PATIENTS SUFFERING FROM ACUTE PROFOUND HEARING LOSS.AURIS MEDICAL HOLDING AG - IN TRIAL FOR AM-111 FDA PROVIDED GUIDANCE ON REGULATORY PATH FORWARD.AURIS MEDICAL - IN WRITTEN RESPONSE FDA ENDORSED CHOICE OF AM-111 PRIMARY, SECONDARY ENDPOINTS, SAFETY ENDPOINTS, AMONG OTHERS.  Full Article

Auris Medical Prices $7 Million Public Offering
Thursday, 12 Jul 2018 09:05pm EDT 

July 12 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL PRICES $7 MILLION PUBLIC OFFERING.AURIS MEDICAL HOLDING- ANNOUNCED PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 17.9 MILLION SHARES, SERIES A WARRANTS TO PURCHASE 6.2 MILLION COMMON SHARES.COMBINED PUBLIC OFFERING PRICE PER UNIT IS $0.39.AURIS MEDICAL -PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF SERIES WARRANTS TO PURCHASE 6.3 MILLION COMMON SHARES.AURIS MEDICAL -PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF SERIES B WARRANTS TO PURCHASE 4.5 MILLION COMMON SHARES.  Full Article

Auris Medical Provides Q1 Loss Per Share CHF 0.30
Tuesday, 15 May 2018 06:45am EDT 

May 15 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL PROVIDES BUSINESS AND STRATEGY UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE CHF 0.30.AURIS-INITIATING PROJECT AM-201 FOR TREATMENT OF HISTAMINERGIC RECEPTOR MEDIATED WEIGHT GAIN,DROWSINESS IN PATIENTS TREATED BY ANTIPSYCHOTIC MEDICATION.REDUCING LEVEL OF OPERATING EXPENSES, WHICH CO BELIEVES WILL RESULT IN REDUCTION OF CASH BURN RATE.CONTINUES TO EXPECT THAT ITS OPERATING EXPENSES IN 2018 WILL BE IN RANGE OF CHF 10 TO 12 MILLION.  Full Article

Auris Medical Announces Further Results From Healos Phase 3 Trial
Thursday, 4 Jan 2018 12:43pm EST 

Jan 4 (Reuters) - Auris Medical Holding Ag ::AURIS MEDICAL HOLDING AG SAYS ANNOUNCED FURTHER CLINICAL RESULTS FROM THE HEALOS PHASE 3 CLINICAL TRIAL, PROVIDES UPDATE ON AM-111 DEVELOPMENT PROGRAM.AURIS MEDICAL HOLDING AG SAYS AM-111 TREATED PATIENTS HAD A LOWER INCIDENCE OF NO HEARING IMPROVEMENT- SEC FILING.AURIS MEDICAL HOLDING SAYS POST-HOC ANALYSES OF TOP-LINE DATA REVEALED CLINICALLY AND STATISTICALLY SIGNIFICANT HEARING IMPROVEMENT WITH AM-111.AURIS MEDICAL HOLDING SAYS PLANS TO DISCUSS ACCUMULATED SAFETY AND EFFICACY DATA AND REGULATORY PATHWAY WITH FDA AND EMA IN Q2 OF 2018..  Full Article

Auris Medical Reports Q3 Loss Per Share CHF 0.14
Tuesday, 28 Nov 2017 06:40am EST 

Nov 28 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE CHF 0.14.‍NET LOSS FOR Q3 OF 2017 WAS CHF 6.0 MILLION, OR CHF 0.14 PER SHARE​.EXPECTS THAT ITS OPERATING EXPENSES IN 2017 WILL BE LOWER THAN PREVIOUS GUIDANCE OF CHF 28 TO 32 MILLION​.‍EXPECTS THAT EXISTING CASH AND CASH EQUIVALENTS WILL ENABLE FUNDING OF OPERATIONS INTO Q2 OF 2018​.  Full Article

Auris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness
Tuesday, 28 Nov 2017 06:40am EST 

Nov 28 (Reuters) - Auris Medical Holding Ag ::AURIS MEDICAL HOLDING AG SAYS ANNOUNCED TOP-LINE RESULTS FROM THE HEALOS PHASE 3 CLINICAL TRIAL OF AM-111 IN SEVERE TO PROFOUND SUDDEN DEAFNESS.AURIS MEDICAL HOLDING AG SAYS HEALOS TRIAL DID NOT MEET PRIMARY EFFICACY ENDPOINT IN OVERALL STUDY POPULATION.AURIS MEDICAL SAYS IN HEALOS TRIAL, CLINICALLY AND STATISTICALLY SIGNIFICANT IMPROVEMENT IN SUBPOPULATION OF PATIENTS WITH PROFOUND ACUTE HEARING LOSS.AURIS MEDICAL SAYS BASED ON FINDINGS FROM HEALOS TRIAL, CONCLUDED THAT SIMILAR DESIGN OF ONGOING ASSENT TRIAL NO LONGER ADEQUATE FOR TESTING AM-111.AURIS MEDICAL HOLDING AG SAYS BASED ON FINDINGS FROM HEALOS TRIAL, ASSENT TRIAL WILL BE TERMINATED EARLY.  Full Article

Auris Medical Holding AG files for resale of up to 7.2 mln common shares
Thursday, 12 Oct 2017 04:37pm EDT 

Oct 12 (Reuters) - Auris Medical Holding Ag :Auris Medical Holding AG files for resale of up to 7.2 million common shares by selling shareholder, LPC Capital Fund Llc‍​ - SEC Filing.  Full Article